Nonlinear oral pharmacokinetics of the α-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1, 4-diazepin-1-yl]quinoline in humans: Use of preclinical data to rationalize clinical observations

Drug Metabolism and Disposition

Volumn 32, Issue 2, 2004, Pages 197-204

  Harrison, Anthony ^a,b   Betts, Alison ^a   Fenner, Katherine ^a   Beaumont, Kevin ^a   Edgington, Alan ^a   Roffey, Sarah ^a   Davis, John ^b   Comby, Pierre ^c   Morgan, Paul ^c  

^a Dept of Pharmacokin Dynam/Metab ^*  (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 (4 CHLOROPHENYL) 6,7 DIMETHOXY 2 [4 (MORPHOLINOCARBONYL)PERHYDRO 1,4 DIAZEPIN 1 YL]QUINOLINE; 4 AMINO 5 (4 FLUOROPHENYL) 6,7 DIMETHOXY 2 [4 (MORPHOLINOCARBONYL)PERHYDRO 1,4 DIAZEPIN 1 YL]QUINOLINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCOPROTEIN P; QUINOLINE DERIVATIVE; UK 294315; UK 298108; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESEARCH; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE ABSORPTION; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; SINGLE BLIND PROCEDURE; SPECIES DIFFERENCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANIMALS; AREA UNDER CURVE; AZEPINES; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MIDDLE AGED; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RETROSPECTIVE STUDIES; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 0842282552     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.2.197     Document Type: Article

References (25)

1. Abel S, Beaumont KC, Crespi CL, Eve MD, Fox L, Hyland R, Jones BC, Muirhead GJ, Smith DA, Venn RF, and Walker DK (2001) Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica 31:665-676.
2. Ayrton A and Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
3. 2 antagonist in rat, dog and human. Xenobiotica 30:627-642.
4. 2 antagonist UK-224,671. Eur J Pharm Sci 12:41-50.
5. Cases A (2000) Doxazosin in a gastrointestinal therapeutic system formulation. Drugs Today 36:679-688.
6. Chiou WL, Jeong HY, Chung SM, and Wu TC (2000) Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res (NY) 17:135-140.
7. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093-1095.
8. De La Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset P, Segura J, and Cami J (2000) Non-linear pharmacokinetics of MDMA ("ecstasy") in humans. Br J Clin Pharmacol 49:104-109.
9. Dressman JB, Amidon GL, Reppas C, and Shah VP (1998) Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res (NY) 15:11-22.
10. Elliott H, Vincent J, Meredith P, and Reid J (1988) Relationship between plasma prazosin concentrations and α-antagonism in humans: comparison of conventional and rate-controlled (Oros) formulations. Clin Pharmacol Ther 43:582-587.
11. Fulton B, Wagstaff AJ, and Sorkin EM (1995) Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 49:295-320.
12. 2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 25:185-197.
13. He Y, Murby S, Warhurst G, Gifford L, Walker D, Ayrton J, Eastmond R, and Rowland M (1998) Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of polyethylene glycol and D peptides. J Pharm Sci 87:626-633.
14. Hunter J and Hirst BH (1997) Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 25:129-157.
15. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, and Grove R (1999) MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28-33.
16. Kajiji S, Dreslin J, Grizzuti K, and Gros P (1994) Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. Biochemistry 33:5041-5048.
17. Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, and Nakanishi O (2002) P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 49:322-328.
18. Milne RJ and Buckley MT (1991) Celiprolol: an updated review of its pharmacokinetic properties and therapeutic efficacy in cardiovascular diseases. Drugs 41:941-969.
19. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, and Fromm M (2000) Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 293:376-382.
20. Roffey S, Cole S, Comby P, Gibson D, Jezequel S, Nedderman A, Smith D, Walker D, and Wood N (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog and human. Drug Metab Dispos 31:731-741.
21. Taipalensuu J, Tornblom H, Lindberg G, Einarssonm C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, and Artursson P (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164-170.
22. Van Kerrebroeck P, Jardin A, Van Cangh P, and Laval K (2002) Long term safety of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open label extension study. Eur Urol 41:54-61.
23. Wandel C, Kim R, Kajiji S, Guengerich P, Wilkinson G, and Wood A (1999) P-Glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944-3948.
24. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, and Langguth P (1996) Evidence for intestinal secretion as an additional clearance pathway for talinolol enantiomers: concentration and dose-dependent absorption in vitro and in vivo. Pharm Res (NY) 13:514-522.
25. Wilde MI and McTavish D (1996) Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 52:883-898.